PMID- 21361908
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20220316
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 164
IP  - 1
DP  - 2011 Apr
TI  - CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant 
      protein-1 and may be useful for early diagnosis.
PG  - 57-65
LID - 10.1111/j.1365-2249.2011.04321.x [doi]
AB  - Human peripheral blood monocytes are a heterogeneous population, including 
      CD14(+) CD16(-) 'classical' monocytes and CD14(+) CD16(+) 'proinflammatory' 
      monocytes. CD16(+) monocytes are expanded in various inflammatory conditions. 
      However, little is known about the CD14(+) CD16(+) monocytes in patients with 
      breast cancer. We detected CD14(+) CD16(+) monocytes in 96 patients with breast 
      cancer and 54 control subjects using flow cytometry. Receiver-operating 
      characteristic (ROC) curve analysis was used to determine the feasibility of 
      CD14(+) CD16(+) monocytes as an indicator for diagnosis of breast cancer. We 
      found that the frequency of CD14(+) CD16(+) monocytes showed a significantly 
      greater increase in breast cancer patients than in controls (16.96% versus 
      10.84%, P < 0.0001). The area under the ROC curve for CD14(+) CD16(+) monocytes 
      was 0.805 [95% confidence interval (95% CI): 0.714-0.877, P = 0.0001]. 
      Furthermore, the levels of CD16(+) monocytes were significantly negatively 
      associated with the tumour size and pathological staging. In vitro, we showed 
      that CD14(+) CD16(+) monocytes were expanded significantly when the purified 
      CD14(+) monocytes were exposed to Michigan Cancer Foundation (MCF)-7 
      cells-conditioned medium (MCF-CM) or, separately, to monocyte chemotactic protein 
      1 (MCP-1). Neutralizing antibodies against MCP-1 inhibited the expansion of 
      CD14(+) CD16(+) monocytes by MCF-CM. Collectively, our findings indicated that 
      MCP-1 can expand CD14(+) CD16(+) monocytes in patients with breast cancer. 
      Furthermore, the CD14(+) CD16(+) monocyte may be a useful indicator in early 
      diagnosis of breast cancer.
CI  - (c) 2011 The Authors. Clinical and Experimental Immunology (c) 2011 British Society 
      for Immunology.
FAU - Feng, A-L
AU  - Feng AL
AD  - Institute of Basic Medical Sciences Department of Obstetrics and Gynecology, Qilu 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Zhu, J-K
AU  - Zhu JK
FAU - Sun, J-T
AU  - Sun JT
FAU - Yang, M-X
AU  - Yang MX
FAU - Neckenig, M R
AU  - Neckenig MR
FAU - Wang, X-W
AU  - Wang XW
FAU - Shao, Q-Q
AU  - Shao QQ
FAU - Song, B-F
AU  - Song BF
FAU - Yang, Q-F
AU  - Yang QF
FAU - Kong, B-H
AU  - Kong BH
FAU - Qu, X
AU  - Qu X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110301
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Chemokine CCL2)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (FCGR3B protein, human)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/diagnosis/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Chemokine CCL2/metabolism
MH  - Culture Media, Conditioned/pharmacology
MH  - Early Diagnosis
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Flow Cytometry
MH  - GPI-Linked Proteins/metabolism
MH  - Humans
MH  - Lipopolysaccharide Receptors/*metabolism
MH  - Middle Aged
MH  - Monocytes/drug effects/*metabolism/pathology
MH  - Receptors, IgG/*metabolism
PMC - PMC3074217
EDAT- 2011/03/03 06:00
MHDA- 2011/06/15 06:00
PMCR- 2012/04/01
CRDT- 2011/03/03 06:00
PHST- 2011/03/03 06:00 [entrez]
PHST- 2011/03/03 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
PHST- 2012/04/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.2011.04321.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2011 Apr;164(1):57-65. doi: 10.1111/j.1365-2249.2011.04321.x. 
      Epub 2011 Mar 1.